<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01259414</url>
  </required_header>
  <id_info>
    <org_study_id>HCC2011A</org_study_id>
    <nct_id>NCT01259414</nct_id>
  </id_info>
  <brief_title>Comparison of Two Solvents Used With Chemotherapy Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma</brief_title>
  <official_title>Comparison of Two Solvents Used With Chemotherapy Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      TACE is considered the standard treatment for unresectable HCC and is widely used as a
      palliative treatment. However there is no consensus of the protocol of TACE.One of the
      variation is does the stability of the suspension by emulsified the lipiodol and the contrast
      medium used to dissolve the anticancer agents really effect the survival.Thus the
      investigators conduct this prospective,randomized controlled study to find out if the
      different method of preparing chemotheraputic drugs can cause a different survival benefit.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transcatheter arterial chemoembolization is currently the mainstays of palliative treatments
      worldwide for patients with unresectable HCC. However there is no standard protocol exists
      for TACE currently. One of the controversy is does the way of emulsified the anticancer
      agents and lipiodol to get a high stability suspension really effect the survival rates.

      Anticancer drugs play important role in survival benefit. Many studies have innovated
      different methods to get a high stability suspension of lipiodol and anticancer drugs
      ,because they think lipiodol can selectively retained in HCC and used as a drug-carrying
      which allow a slow release of the anticancer drug from lipiodol microdroplets. Thus ,A
      stability suspension might get a maximize tumor drug uptake,which can caused a more tumor
      necrosis, and minimize systemic drug levels ,which get a less toxicity, hence survival
      benefit. While the other researcher think a stability emulsion can't get a positive effect
      ,such as pharmacokinetic and systematic toxicity of the anticancer drugs, tumor response,
      biologic response and so on.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">812</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>group1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemoembolization with solvent with specific gravity less than lipiodol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemoembolization with Solvent with specific gravity equivalent to lipiodol</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Solvent with specific gravity less than lipiodol</intervention_name>
    <description>TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in distilled water and emulsified lipiodol followed embolization with polyvinyl alcohol particles (PVA)</description>
    <arm_group_label>group1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Solvent with specific gravity equivalent to lipiodol</intervention_name>
    <description>TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in water-soluble contrast medium and distilled water,then emulsified with lipiodol followed embolization with polyvinyl alcohol particles (PVA)</description>
    <arm_group_label>group2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients &gt; 18 years and &lt;=70 years of age with a diagnosis of HCC

          -  BCLC B stage disease

          -  Not amendable to surgical resection ,local ablative therapy and any other cured
             treatment.

          -  Patients must have at least one tumor lesion that can be accurately measured according
             to EASL criteria. The lesion has not been previously treated with TACE, surgery,
             radiation therapy, radiofrequency ablation, percutaneous ethanol or acetic acid
             injection, or cryoablation.

          -  No Cirrhosis or cirrhotic status of Child-Pugh class A only

          -  Not pregnant or breast-feeding patients

          -  No significant renal impairment (creatinine clearance &lt; 30 mL/minute) or patients on
             dialysis

          -  The following laboratory parameters:

               -  Platelet count ≥ 60,000/µL

               -  Hemoglobin ≥ 8.5 g/dL

               -  Total bilirubin ≤ 1.5 mg/dL Serum albumin ≥ 35 g/L

               -  ASL and AST ≤ 5 x upper limit of normal

               -  Serum creatinine ≤ 1.5 x upper limit of normal

               -  INR ≤ 1.5 or PT/APTT within normal limits

               -  Absolute neutrophil count (ANC) &gt;1,500/mm3

          -  Ability to understand the protocol and to agree to and sign a written informed consent
             document

        Exclusion Criteria:

          -  Known history of HIV

          -  History of organ allograft

          -  Known or suspected allergy to the investigational agents or any agent given in
             association with this trial.

          -  Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy

          -  Evidence of bleeding diathesis.

          -  Patients with clinically significant gastrointestinal bleeding within 30 days prior to
             study entry.

          -  Any other hemorrhage/bleeding event &gt; CTCAE Grade 3 within 4 weeks of first dose of
             study drug

          -  Serious non-healing wound, ulcer, or bone fracture

          -  Known central nervous system tumors including metastatic brain disease

          -  severe Arterioportal Shunts or Arteria vein Shunts
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming Shi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Center, Sun Yat-set University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming Shi</last_name>
    <phone>86-2087343582</phone>
    <phone_ext>86-2087343582</phone_ext>
    <email>shiming@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rong Ping Guo</last_name>
    <phone>86-2087343117</phone>
    <phone_ext>86-2087343117</phone_ext>
    <email>guorongp@mail.sysu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Center Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Shi</last_name>
      <phone>86-2087343582</phone>
      <phone_ext>86-2087343582</phone_ext>
      <email>shiming@mail.sysu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Ping Rong Guo</last_name>
      <phone>86-2087343117</phone>
      <phone_ext>86-2087343117</phone_ext>
      <email>guorongp@mail.sysu.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Ming Shi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Shin SW. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. Korean J Radiol. 2009 Sep-Oct;10(5):425-34. doi: 10.3348/kjr.2009.10.5.425. Epub 2009 Aug 25. Review.</citation>
    <PMID>19721826</PMID>
  </results_reference>
  <results_reference>
    <citation>Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002 May;35(5):1164-71.</citation>
    <PMID>11981766</PMID>
  </results_reference>
  <results_reference>
    <citation>Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002 May 18;359(9319):1734-9.</citation>
    <PMID>12049862</PMID>
  </results_reference>
  <results_reference>
    <citation>Raoul JL, Heresbach D, Bretagne JF, Ferrer DB, Duvauferrier R, Bourguet P, Messner M, Gosselin M. Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer. 1992 Aug 1;70(3):585-90.</citation>
    <PMID>1320447</PMID>
  </results_reference>
  <results_reference>
    <citation>Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005 Nov;42(5):1208-36.</citation>
    <PMID>16250051</PMID>
  </results_reference>
  <results_reference>
    <citation>Takaki Y, Kaminou T, Shabana M, Ihaya T, Otsubo K, Ogawa T. Suitable blending method of lipiodol-cisplatin in transcatheter arterial embolization for hepatocellular carcinoma: evaluation of sustained release and accumulation nature. Hepatogastroenterology. 2008 Jan-Feb;55(81):202-6.</citation>
    <PMID>18507107</PMID>
  </results_reference>
  <results_reference>
    <citation>de Baere T, Zhang X, Aubert B, Harry G, Lagrange C, Ropers J, Dufaux J, Lumbroso J, Rougier P, Ducreux M, Roche A. Quantification of tumor uptake of iodized oils and emulsions of iodized oils: experimental study. Radiology. 1996 Dec;201(3):731-5.</citation>
    <PMID>8939223</PMID>
  </results_reference>
  <results_reference>
    <citation>Takayasu K, Shima Y, Muramatsu Y, Moriyama N, Yamada T, Makuuchi M, Hasegawa H, Hirohashi S. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology. 1987 May;163(2):345-51.</citation>
    <PMID>3031724</PMID>
  </results_reference>
  <results_reference>
    <citation>Tzeng WS, Wu RH, Chang SC, Chou CK, Lin CY, Chen JJ, Yang SC, Lin CH. Ionic versus nonionic contrast media solvents used with an epirubicin-based agent for transarterial chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol. 2008 Mar;19(3):342-50. doi: 10.1016/j.jvir.2007.10.021.</citation>
    <PMID>18295692</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2010</study_first_submitted>
  <study_first_submitted_qc>December 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2010</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Shi Ming</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>Carcinoma,Hepatocellular</keyword>
  <keyword>Liver Neoplasms</keyword>
  <keyword>Survival analysis</keyword>
  <keyword>treatment outcome</keyword>
  <keyword>administration drugs</keyword>
  <keyword>Chemoembolization,</keyword>
  <keyword>TACE</keyword>
  <keyword>polyvinyl alcohol</keyword>
  <keyword>water-soluble contrast mesium</keyword>
  <keyword>iopamidol</keyword>
  <keyword>lipiodol</keyword>
  <keyword>distilled water</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethiodized Oil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

